Pfizer (PFE) closed on the last trading day at $ 36.28, moving -0.06% from the previous trading session. This change lagged behind the S&P 500’s 1.44% daily gain.
Coming in today, shares of the drugmaker had gained 5.55% over the past month. At the same time, the medical sector lost 1%, while the S&P 500 gained 6.26%.
Investors are hoping for PFE’s strength as it approaches its next earnings release, scheduled for May 4, 2021. On that day, PFE is expected to post earnings of $ 0.83 per share, which would represent growth of $ 0.83 per share. year after year. by 3.75%. Meanwhile, our latest consensus estimate calls for revenue of $ 13.42 billion, up 11.54% from the previous year’s quarter.
Looking at the full year, our Zacks consensus estimates suggest that analysts expect earnings of $ 3.25 per share and revenue of $ 59.82 billion. These totals would mark changes of + 46.4% and + 25.55%, respectively, compared to last year.
Investors may also notice recent changes in analyst estimates for the PFE. These revisions generally reflect the latest short-term business trends, which can change frequently. As such, the positive estimate revisions reflect analysts’ optimism about the business and profitability of the company.
Based on our research, we believe that these estimate revisions are directly related to the stock movements of nearby teams. Investors can take advantage of this by using the Zacks rank. This model takes these changes in estimate into account and provides a simple and workable scoring system.
Zacks’ ranking system, which ranges from # 1 (strong buy) to # 5 (strong sell), has an impressive history of externally audited outperformance, with # 1 stocks generating an average annual return of + 25% since then. 1988. Zacks Consensus’s EPS estimate rose 0.89% over the past month. PFE currently has a Zacks rank of # 3 (Hold).
In terms of valuation, PFE is currently trading at a forward P / E ratio of 11.17. This valuation marks a discount compared to the average forward P / E of its sector of 13.32.
Investors should also note that PFE currently has a PEG ratio of 1.66. This popular metric is similar to the widely known P / E ratio, the difference being that the PEG ratio also takes into account the expected growth rate of the company’s earnings. Large Cap Pharmaceuticals shares have, on average, a PEG ratio of 1.9 based on yesterday’s closing prices.
The large-cap pharmaceutical industry is part of the medical sector. This group has a Zacks industry rank of 237, which places it in the bottom 7% of all 250 industries.
The Zacks Industry Rankings assess the strength of our industry groups by measuring the average Zacks rank of individual stocks within groups. Our research shows that the top 50% of industries top the bottom half by a factor of 2 to 1.
To follow PFE in future trading sessions, be sure to use Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today you can download 7 best stocks for the next 30 days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.